{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:25:29Z","timestamp":1784543129001,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Peroxisome proliferator-activated receptor (PPAR) agonists are recognised as a promising treatment for primary biliary cholangitis (PBC). However, the effects and safety of these agonists on PBC remain unexplored. Our study aimed to investigate the efficacy and safety of PPAR agonists in treating PBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Cochrane Library, and Web of Science, PubMed, and Embase databases from inception to 15 March 2024 for randomised controlled studies (RCTs) that enrolled individuals with PBC treated with PPAR agonists compared with placebo. The primary outcomes were biochemical response and normalization of the alkaline phosphatase (ALP) level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight RCTs involving 869 participants in total were included. The meta-analysis revealed that compared to placebo, PPAR agonists increased the rate of biochemical response (RR: 5.53; 95% CI: 3.79, 8.06) and normalization of the ALP level (RR: 17.18; 95% CI: 5.61, 52.61). In addition, PPAR agonists can also reduce alanine aminotransferase (ALT) (MD: \u221212.69 U\/L; 95% CI: \u221218.03, \u22127.35), aspartate aminotransferase (AST) (MD: \u22124.18 U\/L; 95% CI: \u22127.28, \u22121.08), ALP (MD: \u2212142.95 U\/L; 95% CI: \u2212167.29, \u2212118.60), \u03b3-glutamyltransferase (GGT) (MD: \u221263.03 U\/L; 95% CI: \u221292.08, \u221233.98), and total cholesterol (TC) levels (SMD: \u22120.71; 95% CI: \u22121.38, \u22120.04), and there was no significant difference in overall adverse reactions (RR: 0.99; 95% CI: 0.92, 1.05), serious adverse reactions (RR: 1.10; 95% CI: 0.70, 1.72) between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PPAR agonists are safe and well-tolerated in patients with PBC and are effective in improving the rate of biochemical response and related biomarkers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1432814","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:41:41Z","timestamp":1721623301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of peroxisome proliferator-activated receptor agonists for the treatment of primary biliary cholangitis: a meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Gang","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.eclinm.2023.102162","article-title":"Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials","volume":"63","author":"Alesi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: a systematic review and meta-analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol","volume":"108","author":"Ghonem","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00984","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Hatami","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B9","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4","author":"Higgins","year":"2022"},{"key":"B10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/hep.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102227","DOI":"10.1016\/j.clinre.2023.102227","article-title":"Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Jang","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/s2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20406223221114198","DOI":"10.1177\/20406223221114198","article-title":"A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid","volume":"13","author":"Li","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13643-024-02460-0","article-title":"Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis","volume":"13","author":"Lin","year":"2024","journal-title":"Syst. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.cgh.2020.06.062","article-title":"Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy","volume":"19","author":"Montano-Loza","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00795-013-0017-0","article-title":"PPAR\u03b3 ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis","volume":"46","author":"Nozaki","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"835991","DOI":"10.3389\/fphar.2022.835991","article-title":"Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/bph.14886","article-title":"Rosiglitazone alleviates intrahepatic cholestasis induced by \u03b1-naphthylisothiocyanate in mice: the role of circulating 15-deoxy-\u0394(12,14) -PGJ(2) and Nogo","volume":"177","author":"Zhang","year":"2020","journal-title":"Br. J. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1432814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:41:45Z","timestamp":1721623305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1432814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":29,"alternative-id":["10.3389\/fphar.2024.1432814"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1432814","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1432814"}}